At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Macitentandrug
Likely dose
Macitentan 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MERIT-2 : Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerabilty and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
In Brief
A Phase 2 clinical trial evaluating Macitentan for Chronic Thromboembolic Pulmonary Hypertension. Completed, enrolled 76 participants across 33 sites in 15 countries.
Detailed Summary
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, China, Czechia, France, Germany, Hungary, Lithuania, Mexico, Poland, Russia, Switzerland, Thailand, Turkey (Türkiye), Ukraine, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartFeb 2015
Primary CompletionMar 2022
TodayJul 2026
First PostedFeb 12, 2014
Enrollment StartFeb 3, 2015
Primary CompletionMar 21, 2022
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 12.4 years ago
Interventions
Macitentandrug
Macitentan 10mg, oral tablet, once daily